You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder
SBC: LOHOCLA RESEARCH CORPORATION Topic: 150Abstract for Supplement ApplicationThe ultimate goal for our original project was to complete the proof-of-concept work, and the multitude of pharmacodynamic, pharmacokinetic, toxicokinetic, safety, and toxicology studies required by the FDA to apply for an IND. We are fully satisfied that we have generated a new chemical entity that acts at a novel binding site on the GABA-A receptor and acts in ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
SBIR TOPIC 096: Novel Biodegradable Metal Stents for Neonatal Aortic Coarctation
SBC: PEDIASTENT LLC Topic: NHLBIMost stents used to repair congenital heart lesions only need to serve as temporary scaffoldingsBecause pediatric patients have growing cardiovascular structuresthere is great interest in use of bioresorbable stentsBRSfor the treatment of coarctation of the aorta in neonatesA pediatric bioresorbable stent would allow thousands of infants each year to avoid the morbidity and mortality of more invas ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Early Feasibility Clinical Study of the VitalFlow Stimulator, an Emergency Treatment for Ischemic Stroke
SBC: NERVIVE, INC. Topic: 105Stroke is the world’s greatest healthcare burden for which few treatment options are available. The long-term objective of the applicant, Nervive, Inc., is to bring to market a non-invasive medical device, the VitalFlow stimulator, as an emergency treatment for ischemic stroke. The VitalFlow is a novel technology that activates the autonomic components of the facial nerve using pulsed magnetic e ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Clinical Evaluation of a New Middle Ear Diagnostic to Support FDA Regulatory Clearance
SBC: PHOTONICARE INC Topic: NIDCDPROJECT SUMMARY IntroductionPhotoniCareIncis a medical device company nearing commercializing the ClearViewa handheldoptical imaging device for improved diagnosis of middle ear healthThe purpose of this proposaldeveloped in conjunction with the affiliated FDA review committeeis to perform pivotal clinical studies and use the collected data to establish objective data analysis algorithms for FDAkcl ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Real-time volumetric specimen imager for 3D intra-operative lumpectomy margin assessment
SBC: CLARIX IMAGING CORP Topic: 102Project Summary We propose to develop a novel volumetric specimen imagerVSIsystem for significantly reducing breast lumpectomy s reoperation rate and improving cosmetic outcomesAmong the annual performance of andgtlumpectomies in the USaboutof patients need reoperationswhen post surgery pathology examination revealspositive marginindicating incomplete tumor removal in initial surgeryCurrently phys ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Cancer Imaging and Therapy Analysis Platform (CITAP)
SBC: BIOINVISION INC Topic: 102Cancer Imaging and Therapy Analysis PlatformCITAPSummary We will create a preclinicalquantitativeCancer Imaging and Therapy Analysis PlatformCITAPpronounced sea tapwhich will allow one to study cancer biology and optimize pipelines of technologiesimaging agentsimaging methodstargeted nano therapeuticsimmunotherapytumor modelsetcespecially for metastatic and invasive cancersTodayprimary tumor masse ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide
SBC: FirstString Research, Inc Topic: 102PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement to Promote Diversity in Research and Development Small Businesses
SBC: NEUROENE THERAPEUTICS INC Topic: NINDSAbstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease
SBC: DeNovoTherapies LLC Topic: NHLBITBD
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health